FranciscoRobert-VizcarrondoMD
Oncology • Birmingham, ALChief, Hematology/Oncology Birmingham VA Hospital
Are you Dr. Vizcarrondo?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 22 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2000 6th Ave S
Birmingham, AL 35233Phone+1 205-934-9999- Is this information wrong?
Summary
- Dr. Francisco Vizcarrondo, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama. He is affiliated with University of Alabama Hospital and is a Chief at Hematology/Oncology Birmingham VA Hospital.
Education & Training
University of Puerto RicoFellowship, Hematology and Medical Oncology, 1974 - 1976- University of Puerto Rico School of MedicineClass of 1969
Certifications & Licensure
AL State Medical License 1974 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
Publications & Presentations
PubMed
- 9 citationsFirst-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.Khanh T. Do, Laura Q.M. Chow, Karen L. Reckamp, Rachel E. Sanborn, Howard A. Burris, Francisco Robert, D. Ross Camidge, Conor E. Steuer, John H. Strickler, Amy Weise, ...> ;The Oncologist. 2021 Nov 1
- 14 citationsVeliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation...Jeffrey M. Clarke, Jyoti D. Patel, Francisco Robert, Ebenezer A. Kio, Eddie Thara, D. Ross Camidge, Martin Dunbar, Silpa Nuthalapati, Minh H. Dinh, Bruce A. Bach> ;Lung Cancer. 2021 Sep 17
- 5 citationsSWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)Hossein Borghaei, Mary W. Redman, Karen Kelly, Saima N. Waqar, Francisco Robert, Gauri J. Kiefer, Philip J. Stella, Katherine Minichiello, David R. Gandara, Roy S. Her...> ;Clinical Lung Cancer. 2021 May 1
- Join now to see all
Hospital Affiliations
University of Alabama HospitalBirmingham, Alabama
USA Health University HospitalMobile, Alabama
